ASX RELEASE

2 March, 2017

Broker Initiated Coverage - PAR

Hay fever Phase II Trial Nears Completion – Results Readout Q2 – Q3 2017

Paradigm Biopharmaceuticals Ltd (ASX: PAR) The Company wishes to advise that a Broker Report, from Baker Young Stockbrokers, is available on our Website under the Investor Relations section.

Follow this link to the Paradigm website for the complete report:

http://www.paradigmbiopharma.com/investors/media-analyst-reports

FOR FURTHER INFORMATION PLEASE CONTACT:

Paul Rennie
Director & CEO
Paradigm BioPharmaceuticals Ltd
Level 2, 517 Flinders Lane, Melb, VIC, 3000, AUSTRALIA
ABN: 94 169 346 963
Web: http://paradigmbiopharma.com/
Email: prennie@paradigmbiopharma.com
Mobile International: +61 437 778 300
Mobile (Australia): 0437 778 300